Thippeswamy A H M, Sajjan M, Palkar M B, Koti B C, Viswanathaswamy A H M
Department of Pharmacology, K. L. E. S College of Pharmacy, Vidyanagar, Hubli - 580 031, India.
Indian J Pharm Sci. 2010 May;72(3):367-71. doi: 10.4103/0250-474X.70486.
The present study was designed to compare ulcer protective effect of proton pump inhibitors viz. omeprazole, rabeprazole and lansoprazole against dexamethasone plus pylorus ligation induced ulcer model. Dexamethasone (5 mg/kg) was used as an ulcerogen. Dexamethasone suspended in 1% CMC in water was given orally to all the rats 15 min after the pylorus ligation. Omeprazole (20 mg/kg), rabeprazole (20 mg/kg), and lansoprazole (20 mg/kg) were administered by oral route 30 min prior to ligation was used for ulcer protective studies, gastric secretion and mucosal studies. Effects of proton pump inhibitors were determined by the evaluation of various biochemical parameters such as ulcer index, free and total acidity, gastric pH, mucin, pepsin and total proteins. Oral administration of proton pump inhibitors showed significant reduction in gastric acid secretion and ulcer protective activity against dexamethasone plus pylorus ligation induced ulcer model. The % protection of omeprazole, rabeprazole and lansoprazole was 84.04, 89.36 and 79.78, respectively. Rabeprazole significantly inhibited the acid-pepsin secretion and increased the gastric mucin secretion. The observations made in the present study suggest that rabeprazole is the most effective gastric antisecretory and ulcer healing agent as compared to omeprazole and lansoprazole.
本研究旨在比较质子泵抑制剂奥美拉唑、雷贝拉唑和兰索拉唑对由地塞米松加幽门结扎诱导的溃疡模型的溃疡保护作用。地塞米松（5毫克/千克）用作致溃疡剂。幽门结扎15分钟后，将悬浮于1%羧甲基纤维素钠水溶液中的地塞米松口服给予所有大鼠。在结扎前30分钟，通过口服途径给予奥美拉唑（20毫克/千克）、雷贝拉唑（20毫克/千克）和兰索拉唑（20毫克/千克），用于溃疡保护研究、胃液分泌和黏膜研究。通过评估各种生化参数，如溃疡指数、游离酸度和总酸度、胃pH值、黏蛋白、胃蛋白酶和总蛋白，来确定质子泵抑制剂的作用。口服质子泵抑制剂显示出对由地塞米松加幽门结扎诱导的溃疡模型的胃酸分泌和溃疡保护活性有显著降低。奥美拉唑、雷贝拉唑和兰索拉唑的保护率分别为84.04%、89.36%和79.78%。雷贝拉唑显著抑制酸-胃蛋白酶分泌并增加胃黏蛋白分泌。本研究中的观察结果表明，与奥美拉唑和兰索拉唑相比，雷贝拉唑是最有效的胃抗分泌和溃疡愈合药物。
